Sofosbuvir subsidised in Australia for hepatitisC

Sofosbuvir subsidised in Australia for hepatitisC PharmacoEconomics & Outcomes News 784, p37 - 12 Aug 2017 Sofosbuvir subsidised in Australia for hepatitis C Sofosbuvir (Epclusa) will be subsidised in Australia for the treatment of hepatitis C from 1 August 2017, via the Pharmaceutical Benefits Scheme (PBS). Sofosbuvir is the first of the new direct acting antivirals that can be used in the treatment of patients with any genotype of hepatitis and has an expected success rate of 90%. Up to 200 000 Australians are infected with hepatitis C, with approximately 800 people dying from the infection each year. The newly announced government funding will reduce the treatment cost to the patient to a maximum of $A38.80 per month, with the concessional price being just $6.30, compared with unsubsidised costs of over $20 000 per treatment. "Eliminating hepatitis C from Australia will take a coordinated effort from GPs, specialists, nurses, patients and the Government", commented Minister for Health, the Hon. Greg Hunt MP. "Today is World Hepatitis Day and I want to reiterate the Government’s commitment to eliminate hepatitis C in Australia by 2030". Over 42 000 Australians have benefited from PBS- subsidised medicine for chronic hepatitis C since Australia became one of the first countries in the world to subsidise new medicines for all adults with chronic infection. As well as allocating over $1 billion for these new medicines over the next five years through the PBS, the Australian government is providing education to health professionals about hepatitis B and C, as well as funding hepatitis B vaccination for all infants. Additionally, free catch-up vaccines became available on 1 July 2017 for all refugees, humanitarian entrants and 10 to 19-year-olds through the National Immunisation Program. Hon Greg Hunt MP, Minister for Health, Minister for Sport. New drug to help over 200,000 Australians. Internet Document : 28 Jul 2017. Available from: URL: yr2017-hunt072.htm 803262349 1173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 12 Aug 2017 No. 784 PharmacoEconomics & Outcomes News Springer Journals

Sofosbuvir subsidised in Australia for hepatitisC

1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
Publisher site
See Article on Publisher Site

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial